摘要
目的对比小剂量美卓乐联合班布特罗片与舒利迭治疗慢性阻塞性肺疾病（COPD）稳定期的成本与效用。方法选取我院2014年6月~2016年2月呼吸内科住院治疗的100例COPD患者作为研究对象,按照入院治疗的先后顺序分为A、B组,每组各50例。A组应用小剂量美卓尔联合班布特罗片治疗,B组患者应用舒利迭治疗。对比两组的临床治疗效果及治疗费用。结果两组临床治疗效果接近,差异无统计学意义（P〉0.05）。两组治疗后肺功能均较治疗前改善（均P〈0.05）,两组治疗后肺功能改善情况接近,差异无统计学意义（P〉0.05）。A组治疗过程中费用显著少于B组,差异有统计学意义（P〈0.05）。结论通过分析美卓乐联合班布特罗对比舒利迭治疗COPD的成本及效用,在相同疗效前提下,美卓乐联合班布特罗具有疗效稳定、价格低廉、副作用少的特点,可减轻患者负担,合理调整卫生资源,值得临床广泛推广应用。
Objective To compare the cost-effect of a small dose of medrol combining with bambuterol in the treatment of chronic obstructive pulmonary disease（COPD） at a stable stage in comparison with that by seretide. Methods From June 2014 to February 2016,100 hospitalized patients with COPD in department of respiration medicine in our hospital were selected as research objects.According to the sequence of treatment,they were evenly divided into group A and group B.In group A,a small dose of medrol combining with bambuterol was adopted,while in group B,seretide was provided.The clinical therapeutic effect and treatment cost in two groups were compared. Results The clinical effect in group A and B was similar without a statistical difference（P 0.05）.After treatment, the pulmonary function in two groups was both improved（both P0.05）.Improvement of pulmonary function in two groups after treatment was similar without a significant difference（P 0.05）.Treatment cost in group A was significantly less than that in group B,which was displayed a statistical difference（P0.05）. Conclusion By analyzing the cost-effect of medrol combining with bambuterol in the treatment of COPD in comparison with that by seretide,at premise of similar effect,the former has advantages of stable effect,low cost,and few side effects,which reduces patient′ s burden,reasonably adjusts health resources,and is worthy of extensive promotion and application in clinic.
出处
《中国当代医药》
2016年第12期83-85,88,共4页
China Modern Medicine
基金
广东省云浮市科技计划项目(2014B61)
关键词
美卓尔
班布特罗
舒利迭
COPD
成本-效用
Medrol
Bambuterol
Seretide
Chronic obstructive pulmonary disease（COPD）
Cost-effect
